AEON Biopharma Investors Contribute Additional $20 Million to SPAC Deal
By IPO Edge Editorial Staff Biopharmaceutical company AEON Biopharma, Inc. has raised an additional $20 million in funding from existing investors to support its going-public transaction with Priveterra Acquisition Corp. (Nasdaq: PMGM). The additional capital represents nearly half of the...